Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Items 201–300 of 1,000
Triptolide with Potential Medicinal Value for Diseases of the Central Nervous System
Zheng, Y., Zhang, W., & Wang, X. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12039 · Cited by 89
Wang, Q., Li, W.-X., Dai, S.-X., Guo, Y.-C., Han, F.-F., Zheng, J.-J., Li, G.-H., & Huang, J.-F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161032 · Cited by 88
“In this study, we performed meta-analyses of gene expression data of two neurodegenerative diseases, PD and AD [1].”
MethodAhyayauch, H., Raab, M., Busto, J. V., Andraka, N., Arrondo, J.-L. R., Masserini, M., Tvaroška, I., & Goñi, F. M. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.06.043 · Cited by 90
Biological functions of selenium and its potential influence on Parkinson's disease
Ellwanger, J. H., Franke, S. I. R., Bordin, D. L., Prá, D., & Henriques, J. A. P. (2016) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201620150595 · Cited by 91
The hereditary mutation G51D unlocks a distinct fibril strain transmissible to wild-type α-synuclein
Sun, Y., Long, H., Xia, W., Wang, K., Zhang, X., Sun, B., Cao, Q., Zhang, Y., Dai, B., Li, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26433-2 · Cited by 99
Byl, N. N., Zhang, W., Coo, S., & Tomizuka, M. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.04.020 · Cited by 91
APOE-ε4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease
Hou, M., Xu, G., Ran, M., Luo, W., & Wang, H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.619051 · Cited by 77
Subjective Complaints Precede Parkinson Disease: The Rotterdam Study
de Lau, L. M. L., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.noc50312 · Cited by 86
Back to the future: the 'old-fashioned' way to new medications for neurodegeneration
Lansbury, P. T. (2004) · Nature Medicine · doi:10.1038/nrn1435 · Cited by 93
Genomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease
Talwar, P., Silla, Y., Grover, S., Gupta, M., Agarwal, R., Kushwaha, S., & Kukreti, R. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-199 · Cited by 86
Wu, Y., Gong, Y., Luan, Y., Li, Y., Liu, J., Yue, Z., Yuan, B., Sun, J., Xie, C., Li, L., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201901984r · Cited by 91
Characterization of α-Synuclein Interactions with Selected Aggregation-Inhibiting Small Molecules
Rao, J. N., Dua, V., & Ulmer, T. S. (2008) · Biochemistry · doi:10.1021/bi8002378 · Cited by 88
Increased Risk of Dementia in Patients With Chronic Obstructive Pulmonary Disease
Liao, K.-M., Ho, C.-H., Ko, S.-C., & Li, C.-Y. (2015) · Medicine · doi:10.1097/md.0000000000000930 · Cited by 83
Peluso, S., De Rosa, A., De Lucia, N., Antenora, A., Illario, M., Esposito, M., & De Michele, G. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718774634 · Cited by 65
Tumor necrosis factor-α−308A/G polymorphism is associated with age at onset of Alzheimer's disease
Lio, D., Annoni, G., Licastro, F., Crivello, A., Forte, G. I., Scola, L., Colonna‐Romano, G., Candore, G., Arosio, B., Galimberti, L., et al. (2006) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.01.015 · Cited by 91
“Genetic factors have been found to be associated with the sporadic form of the disease, and the ApoliproteinE(APOE)4 allele significantly increases the risk of AD (Myers and Goate, 2001; Nussbaum and Ellis, 2003).”
A proteomic approach in the study of an animal model of Parkinson's disease
Iuliis, A. D., Grigoletto, J., Recchia, A., Giusti, P., & Arslan, P. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2005.03.028 · Cited by 89
Discovery of Oxadiazoyl Tertiary Carbinamine Inhibitors of β-Secretase (BACE-1)
Rajapakse, H. A., Nantermet, P. G., Selnick, H. G., Munshi, S. K., McGaughey, G. B., Lindsley, S. R., Young, M. B., Lai, M., Espeseth, A. S., Shi, X., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061046r · Cited by 92
Between destiny and disease: Genetics and molecular pathways of human central nervous system aging
Glorioso, C., & Sibille, E. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.11.006 · Cited by 80
Cheng, Y.-F., Zhu, G., Wang, M., Cheng, H. D., Zhou, A., Wang, N., Fang, N., Wang, X., Xiao, X., Chen, Z., et al. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.10.009 · Cited by 84
Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release
Berger, A. K., Cortese, G. P., Amodeo, K. D., Weihofen, A., Letai, A., & LaVoie, M. J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp384 · Cited by 83
Speech- and language-based classification of Alzheimer's disease: a systematic review
Vigo, I., Coelho, L., & Reis, S. (2022) · Bioengineering · doi:10.3390/bioengineering9010027 · Cited by 83
Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimerʼs Disease
Bassil, N., & Grossberg, G. T. (2009) · CNS Drugs · doi:10.2165/00023210-200923040-00003 · Cited by 95
Endoplasmic Reticulum Enrollment in Alzheimer’s Disease
Viana, R. J. S., Nunes, A. F., & Rodrigues, C. M. P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8301-x · Cited by 89
Farley, B. G., Fox, C., Ramig, L. O., & McFarland, D. H. (2008) · Topics in Geriatric Rehabilitation · doi:10.1097/01.tgr.0000318898.87690.0d · Cited by 104
Fajardo, V. A., Fajardo, V. A., LeBlanc, P. J., & MacPherson, R. E. K. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170744 · Cited by 77
Alcoholism: A Multi-Systemic Cellular Insult to Organs
Dguzeh, U., Haddad, N., Smith, K. T. S., Johnson, J., Doye, A. A., Gwathmey, J. K., & Haddad, G. E. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15061083 · Cited by 84
“Although genetics and environmental exposures are recognized as contributors to Parkinson’s disease, researchers have also begun to investigate the relationship between alcohol consumption and the occurrence of Parkinson’s disease [41].”
BackgroundWearable sensor-based gait analysis to discriminate early Parkinson’s disease from essential tremor
Lin, S., Gao, C., Li, H., Huang, P., Ling, Y., Chen, Z., Ren, K., & Chen, S. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11577-6 · Cited by 88
Caspases in Alzheimer’s Disease: Mechanism of Activation, Role, and Potential Treatment
Wójcik, P., Jastrzębski, M. K., Zięba, A., Matosiuk, D., & Kaczor, A. A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03847-1 · Cited by 90
He, S., Huang, L., Shao, C., Nie, T., Xia, L., Cui, B., Lu, F., Zhu, L., Chen, B., & Yang, Q. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00249-y · Cited by 80
Das, R. C., Rauf, A., Akhter, S., Islam, M. N., Emran, T. B., Mitra, S., Khan, I. N., & Mubarak, M. S. (2021) · Molecules · doi:10.3390/molecules26123696 · Cited by 83
John, S., Thangapandian, S., Sakkiah, S., & Lee, K. W. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-s1-s28 · Cited by 82
“The AD is a debilitating neurodegenerative disease that results in the irreversible loss of neurons, particularly in the cortex and hippocampus [3].”
BackgroundExpression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease
Liu, W. W., Johnston, J. A., Todd, S. A., Coulson, D. T. R., Murphy, S., Irvine, G. B., & Passmore, A. P. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051096 · Cited by 71
Is insulin-like growth factor-1 involved in Parkinson’s disease development?
Castilla-Cortázar, I., Aguirre, G. A., Femat-Roldán, G., Martín-Estal, I., & Espinosa, L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02223-0 · Cited by 73
Assessing the contribution of the chemical exposome to neurodegenerative disease
Lefèvre‐Arbogast, S., Chaker, J., Mercier, F., Barouki, R., Coumoul, X., Miller, G. W., David, A., & Samieri, C. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01627-1 · Cited by 81
Platelet β-secretase activity is increased in Alzheimer's disease
Johnston, J. A., Liu, W. W., Coulson, D. T. R., Todd, S., Murphy, S., Brennan, S., Foy, C. J., Craig, D., Irvine, G. B., & Passmore, A. P. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.003 · Cited by 84
Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases
Giménez, V. M. M., Heras, N. D. L., Lahera, V., Tresguerres, J. A. F., Reiter, R. J., & Manucha, W. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.888292 · Cited by 83
Glycogen synthase kinase‐3β and tau genes interact in Alzheimer's disease
Kwok, J. B. J., Loy, C. T., Hamilton, G., Lau, E., Hallupp, M., Williams, J., Owen, M. J., Broe, G. A., Tang, N., Lam, L., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21476 · Cited by 78
Batista, A. F., Bodart‐Santos, V., Felice, F. G. D., & Ferreira, S. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0593-6 · Cited by 77
Cell toxicity and conformational disease
Carrell, R. W. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.09.005 · Cited by 77
Alternative oxidase rescues mitochondria-mediated dopaminergic cell loss in Drosophila
Humphrey, D. M., Parsons, R. B., Ludlow, Z. N., Riemensperger, T. D., Esposito, G., Verstreken, P., Jacobs, H. T., Birman, S., & Hirth, F. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds096 · Cited by 81
A Heterogeneous Sensing Suite for Multisymptom Quantification of Parkinson’s Disease
Huo, W., Angeles, P., Tai, Y., Pavese, N., Wilson, S., Hu, M. T., & Vaidyanathan, R. (2020) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2020.2978197 · Cited by 84
Mrozik, K. M., Zilm, P. S., Bagley, C. J., Hack, S., Hoffmann, P., Gronthos, S., & Bartold, P. M. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0446 · Cited by 84
Kolisek, M., Sponder, G., Mastrototaro, L., Smorodchenko, A., Launay, P., Vormann, J., & Schweigel-Röntgen, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071096 · Cited by 74
Screening for Memory Disorders, Dementia and Alzheimer’s Disease
Ashford, J. W. (2008) · Aging Health · doi:10.2217/1745509x.4.4.399 · Cited by 81
He, Z.-X., Chen, X.-W., Zhou, Z.-W., & Zhou, S.-F. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2015.1101131 · Cited by 83
Default mode network differences between rigidity- and tremor-predominant Parkinson's disease
Karunanayaka, P. R., Lee, E.-Y., Lewis, M. M., Sen, S., Eslinger, P. J., Yang, Q. X., & Huang, X. (2016) · Cortex · doi:10.1016/j.cortex.2016.04.021 · Cited by 70
Perez-Pardo, P., de Jong, E. M., Broersen, L. M., van Wijk, N., Attali, A., Garssen, J., & Kraneveld, A. D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00057 · Cited by 74
“Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD; de Rijk et al., 2000; Nussbaum and Ellis, 2003).”
BackgroundAlzheimer’s Disease: A Clinical Practice-Oriented Review
Alves, L., Correia, A. S. A., Miguel, R., Alegria, P., & Bugalho, P. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00063 · Cited by 68
Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer's disease
Zekanowski, C., & Wojda, U. (2009) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2009-1748 · Cited by 73
Loss of nuclear REST/NRSF in aged-dopaminergic neurons in Parkinson’s disease patients
Kawamura, M., Sato, S., Matsumoto, G., Fukuda, T., Shiba‐Fukushima, K., Noda, S., Takanashi, M., Mori, N., & Hattori, N. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.042 · Cited by 77
“It is predicted that PD affects over 1% of the population at age 60, but the rate of PD is five times higher by age 80, suggesting that senescence of the brain or neurons is related to the onset of PD [2] [9] [16].”
The Epidemiological Scale of Alzheimer’s Disease
Cornutiu, G. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2106w · Cited by 70
Herrán, E., Ruíz-Ortega, J. Á., Aristieta, A., Igartúa, M., Requejo, C., Lafuente, J. V., Ugedo, L., Pedraz, J. L., & Hernández, R. M. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.03.034 · Cited by 79
Klein, C., Schneider, S. A., & Lang, A. E. (2009) · Movement Disorders · doi:10.1002/mds.22675 · Cited by 72
Initial management of Parkinson's disease
Goetz, C. G., & Pal, G. D. (2014) · BMJ · doi:10.1136/bmj.g6258 · Cited by 82
Effectiveness of tai chi for Parkinson's disease: A critical review
Lee, M. S., Lam, P., & Ernst, E. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.02.003 · Cited by 82
“0% among people aged 65e69 years, and rises to 1e3% among those aged 80 years and over [1].”
BackgroundAlcohol Consumption and Parkinson’s Disease Risk: A Review of Recent Findings
Bettiol, S. S., Rose, T. C., Hughes, C. J., & Smith, L. A. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150533 · Cited by 72
The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases
Jiang, H., Gong, T., & Zhou, R. (2019) · Advances in immunology · doi:10.1016/bs.ai.2019.11.003 · Cited by 75
Parkinson's disease proteins: Novel mitochondrial targets for cardioprotection
Mukherjee, U., Ong, S., Ong, S., & Hausenloy, D. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.005 · Cited by 77
“The prevalence of PD in industrialized countries is estimated at 0.3% of the entire population (Nussbaum & Ellis, 2003) and approximately 1.0% of the population over the age of 60 is affected (Abou-Sleiman et al., 2006).”
BackgroundInfluentialWang, J., Yang, Q. X., Sun, X., Vesek, J., Mosher, Z. A., Vasavada, M. M., Chu, J., Kanekar, S. G., Shivkumar, V., Venkiteswaran, K., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.03.012 · Cited by 75
“Idiopathic Parkinson's disease (PD) is the second most common neurodegenerative disorder and affects over four million people around the world [1].”
BackgroundSORL1 haplotypes modulate risk of Alzheimer's disease in Chinese
Tan, E., Lee, J., Chen, C., Teo, Y. Y., Zhao, Y., & Lee, W. L. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.10.013 · Cited by 75
Inpatient Management of Parkinson Disease: Current Challenges and Future Directions
Oguh, O., & Videnović, A. (2011) · The Neurohospitalist · doi:10.1177/1941874411427734 · Cited by 77
“6% in people over 65 years of age, rising up to 3% in people over 80 years of age.(1) According to the recent epidemiological data, the number of individuals affected by PD in the most populous nations worldwide is expected to rise and will double within the next several decades.”
BackgroundTracking Parkinson’s: Study Design and Baseline Patient Data
Malek, N., Swallow, D. M. A., Grosset, K. A., Lawton, M., Marrinan, S. L., Lehn, A., Bresner, C., Bajaj, N. P. S., Barker, R. A., Ben‐Shlomo, Y., et al. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150662 · Cited by 71
Kim, C.-B., Choi, Y. Y., Song, W. K., & Song, K. (2013) · Journal of Biomedical Optics · doi:10.1117/1.jbo.19.5.051205 · Cited by 72
Alipour Nosrani, E., Tamtaji, O. R., Alibolandi, Z., Sarkar, P., Ghazanfari, M., Azami Tameh, A., Taghizadeh, M., Banikazemi, Z., Hadavi, R., & Naderi Taheri, M. (2021) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2020.1833917 · Cited by 69
“1–3% among old individuals over 65 years of age.([1]) PD is mostly acknowledged as a movement disorder.”
BackgroundWood, L. D. (2010) · Drugs & Aging · doi:10.2165/11318330-000000000-00000 · Cited by 82
Zeng, S.-Y., Liu, Y., Liu, J., Zeng, Z., Xie, H., & Liu, J. (2023) · Aging and Disease · doi:10.14336/ad.2023.0325 · Cited by 73
Huang, H., La, D. S., Cheng, A. C., Whittington, D. A., Patel, V. F., Chen, K., Dineen, T. A., Epstein, O. I., Graceffa, R. F., Hickman, D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300598e · Cited by 70
Tricyclic Polyprenylated Acylphloroglucinols from St John’s Wort, Hypericum perforatum
Guo, Y., Zhang, N., Chen, C., Huang, J., Li, X., Liu, J., Zhu, H., Tong, Q., Zhang, J., Luo, Z., et al. (2017) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b01178 · Cited by 69
Pharmacological effects of Astragalus polysaccharides in treating neurodegenerative diseases
Shi, Y., & Ma, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1449101 · Cited by 72
“It is estimated that the prevalence of PD in the general population is 0.3%, about 1% in people over 60 years old, and about 3% in people over 80 years old, with an incidence of 8 – 18 per 100,000 person-years (Tanner and Goldman, 1996; Nussbaum and Ellis, 2003).”
BackgroundInfluentialSequestration of essential proteins causes prion associated toxicity in yeast
Vishveshwara, N., Bradley, M. E., & Liebman, S. W. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06836.x · Cited by 72
Risk of fracture in patients with Parkinson’s disease
Pouwels, S., Bazelier, M. T., de Boer, A., Weber, W. E. J., Neef, C., Cooper, C. C., & de Vries, F. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2300-2 · Cited by 68
“Parkinson’s disease (PD) is a movement disorder with a prevalence of about 1 % in people over 60 years of age [1].”
BackgroundOrdemann, J. M., & Austin, R. N. (2016) · Metallomics · doi:10.1039/c5mt00300h · Cited by 76
Hsp110 mitigates α-synuclein pathology in vivo
Taguchi, Y. V., Gorenberg, E. L., Nagy, M., Thrasher, D. R., Fenton, W. A., Volpicelli‐Daley, L. A., Horwich, A. L., & Chandra, S. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903268116 · Cited by 71
Alzheimer’s disease: epidemiology, genetics, and beyond
Wang, X., & Ding, H. (2008) · Neuroscience Bulletin · doi:10.1007/s12264-008-0105-7 · Cited by 83
“Although about one percent of individuals at the age of 65 are affected, the number increases quickly to about 50% for those people who are 95 or older[11].”
BackgroundNabers, A., Ollesch, J., Schartner, J., Kötting, C., Genius, J., Haußmann, U., Klafki, H., Wiltfang, J., & Gerwert, K. B. (2015) · Journal of Biophotonics · doi:10.1002/jbio.201400145 · Cited by 70
Neuroprotective benefits of grape seed and skin extract in a mouse model of Parkinson’s disease
Ben Youssef, S., Brisson, G., Doucet-Beaupré, H., Castonguay, A.-M., Gora, C., Amri, M., & Lévesque, M. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1616435 · Cited by 64
Constipation in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Yao, L., Liang, W., Chen, J., Wang, Q., & Huang, X. (2022) · European Neurology · doi:10.1159/000527513 · Cited by 71
T1rho (T1ρ) MR imaging in Alzheimer’ disease and Parkinson’s disease with and without dementia
Haris, M., Singh, A., Cai, K., Davatzikos, C. A., Trojanowski, J. Q., Melhem, E. R., Clark, C. M., & Borthakur, A. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5762-6 · Cited by 70
Modulation of inflammatory pathways by the immune cholinergic system
Nizri, E., & Brenner, T. (2011) · Amino Acids · doi:10.1007/s00726-011-1192-8 · Cited by 68
Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement
Stojakovic, A., Paz-Filho, G., Arcos-Burgos, M., Licinio, J., Wong, M.-L., & Mastronardi, C. A. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9988-x · Cited by 64
Overexpression of α‐synuclein in an astrocyte cell line promotes autophagy inhibition and apoptosis
Erustes, A. G., Stefani, F. Y., Terashima, J. Y., Stilhano, R. S., Monteforte, P. T., da Silva Pereira, G. J., Han, S. W., Calgarotto, A. K., Hsu, Y., Ureshino, R. P., et al. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24092 · Cited by 64
“Parkinson disease (PD) is a disease directly linked to age, affecting 0.5% to 1% of persons 65 to 69 years old, increasing to 1% to 3% in populations 80 years and older (Nussbaum & Ellis, 2003).”
BackgroundInfluentialRosario, D., Boren, J., Uhlen, M., Proctor, G., Aarsland, D., Mardinoglu, A., & Shoaie, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00716 · Cited by 67
Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Westmark, C. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.122 · Cited by 74
Yamazaki, Y., Takahashi, T., Hiji, M., Kurashige, T., Izumi, Y., Yamawaki, T., & Matsumoto, M. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.04.038 · Cited by 75
Epidemiology of complementary and alternative medicine use in patients with Parkinson’s disease
Wang, Y., Xie, C., Wang, W., Lü, L., Fu, D.-L., Wang, X., & Zheng, G. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.10.022 · Cited by 70
Wang, Q., Xiao, B., Cui, S., Song, H., Qian, Y., Dong, L., An, H., Cui, Y., Zhang, W., He, Y., et al. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.018218 · Cited by 68
Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients
Klietz, M., Greten, S., Wegner, F., & Höglinger, G. U. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00654-z · Cited by 66
Parada, C., Gato, A., & Bueno, D. (2005) · Journal of Proteome Research · doi:10.1021/pr050213t · Cited by 67
Profiling of Parkin-Binding Partners Using Tandem Affinity Purification
Zanon, A., Rakovic, A., Blankenburg, H., Doncheva, N. T., Schwienbacher, C., Serafin, A., Alexa, A., Weichenberger, C. X., Albrecht, M., Klein, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078648 · Cited by 61
A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders
Britzolaki, A., Saurine, J., Klocke, B., & Pitychoutis, P. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12457-1_6 · Cited by 68
Biomarkers in Parkinsonʼs disease: an update
Shtilbans, A., & Henchcliffe, C. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283550c0d · Cited by 60
Translational molecular imaging and drug development in Parkinson’s disease
Haider, A., Elghazawy, N. H., Dawoud, A., Gebhard, C., Wichmann, T., Sippl, W., Hoener, M. C., Arenas, E., & Liang, S. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00600-z · Cited by 64
Increased suicide risk and clinical correlates of suicide among patients with Parkinson's disease
Lee, T., Lee, H. B., Ahn, M. H., Kim, J., Kim, M. S., Chung, S. J., & Hong, J. P. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.09.006 · Cited by 69
Anti-inflammatory drugs and Alzheimer's disease
Martyn, C. N. (2003) · BMJ · doi:10.1136/bmj.327.7411.353 · Cited by 63
Moskvina, V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.448 · Cited by 61
The Impact of Alzheimer's Disease on the Chinese Economy
Keogh-Brown, M. R., Jensen, H. T., Arrighi, H. M., & Smith, R. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.019 · Cited by 64
Barrow, J. C., Stauffer, S. R., Rittle, K. E., Ngo, P. L., Yang, Z.-Q., Selnick, H. G., Graham, S. L., Munshi, S. K., McGaughey, G. B., Holloway, M. K., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800914n · Cited by 65
Post-traumatic Stress Disorder and Risk of Parkinson Disease: A Nationwide Longitudinal Study
Chan, Y. E., Bai, Y., Hsu, J.-W., Huang, K., Su, T., Li, C., Lin, W.-C., Pan, T., Chen, T., Tsai, S., et al. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.03.012 · Cited by 64
Zdunić, G. M., Aradski, A. A., Gođevac, D. M., Živković, J., Duletić-Laušević, S. N., Krstić‐Milošević, D., & Šavikin, K. (2020) · Industrial Crops and Products · doi:10.1016/j.indcrop.2020.112328 · Cited by 61
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.